Pioglitazone, a PPARγ activator, has been proved to reduce TNFα, TGFβ, and monocyte chemoattractant protein-1 and attenuate myocyte hypertrophy and interstitial fibrosis in MI mice [61]. Here, PPARG is linked to myocardial infarction.